HEIDI MARCOZZI: Open Payments
NPI 1316319973 · ANNAPOLIS, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$513 in 23 payments from 15 companies in 2025. Trend: 2023 $279 · 2024 $694 · 2025 $513
Food & beverage: $513
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 3 | $78 |
| PFIZER INC. | 3 | $74 |
| ABBVIE INC. | 2 | $57 |
| Astellas Pharma US Inc | 2 | $50 |
| Lilly USA, LLC | 2 | $43 |
| Novo Nordisk Inc | 2 | $36 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Amgen Inc. | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Exact Sciences Corporation | 1 | $21 |
Products named: VRAYLAR, Veozah, CAPVAXIVE, MOUNJARO, Rybelsus, NURTEC ODT, GARDASIL 9, PREVNAR 20.
Industry payments across MD — which companies pay providers there.
